299 related articles for article (PubMed ID: 10404318)
1. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action.
Zhai L; Chen M; Blom J; Theander TG; Christensen SB; Kharazmi A
J Antimicrob Chemother; 1999 Jun; 43(6):793-803. PubMed ID: 10404318
[TBL] [Abstract][Full Text] [Related]
2. Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani.
Chen M; Christensen SB; Theander TG; Kharazmi A
Antimicrob Agents Chemother; 1994 Jun; 38(6):1339-44. PubMed ID: 8092835
[TBL] [Abstract][Full Text] [Related]
3. Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania.
Chen M; Christensen SB; Blom J; Lemmich E; Nadelmann L; Fich K; Theander TG; Kharazmi A
Antimicrob Agents Chemother; 1993 Dec; 37(12):2550-6. PubMed ID: 8109916
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones.
Chen M; Zhai L; Christensen SB; Theander TG; Kharazmi A
Antimicrob Agents Chemother; 2001 Jul; 45(7):2023-9. PubMed ID: 11408218
[TBL] [Abstract][Full Text] [Related]
5. The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria.
Zhai L; Blom J; Chen M; Christensen SB; Kharazmi A
Antimicrob Agents Chemother; 1995 Dec; 39(12):2742-8. PubMed ID: 8593012
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of antileishmanial and antimalarial chalcones.
Liu M; Wilairat P; Croft SL; Tan AL; Go ML
Bioorg Med Chem; 2003 Jul; 11(13):2729-38. PubMed ID: 12788347
[TBL] [Abstract][Full Text] [Related]
7. Development of Leishmania donovani stably expressing DsRed for flow cytometry-based drug screening using chalcone thiazolyl-hydrazone as a new antileishmanial target.
Jaiswal AK; Rao KB; Kushwaha P; Rawat K; Modukuri RK; Khare P; Joshi S; Mishra S; Rai A; Sashidhara KV; Dube A
Int J Antimicrob Agents; 2016 Dec; 48(6):695-702. PubMed ID: 27876275
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of chalcones as potential antileishmanial agents.
Gupta S; Shivahare R; Korthikunta V; Singh R; Gupta S; Tadigoppula N
Eur J Med Chem; 2014 Jun; 81():359-66. PubMed ID: 24858541
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani.
Zhang R; Shang L; Jin H; Ma C; Wu Y; Liu Q; Xia Z; Wei F; Zhu XQ; Gao H
Parasitol Res; 2010 Jul; 107(2):475-9. PubMed ID: 20495931
[TBL] [Abstract][Full Text] [Related]
11. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
[TBL] [Abstract][Full Text] [Related]
12. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
Jain SK; Sahu R; Walker LA; Tekwani BL
J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of ferrocenylquinoline as a potential antileishmanial agent.
Yousuf M; Mukherjee D; Pal A; Dey S; Mandal S; Pal C; Adhikari S
ChemMedChem; 2015 Mar; 10(3):546-54. PubMed ID: 25619822
[TBL] [Abstract][Full Text] [Related]
14. Identification of chalcone-based antileishmanial agents targeting trypanothione reductase.
Ortalli M; Ilari A; Colotti G; De Ionna I; Battista T; Bisi A; Gobbi S; Rampa A; Di Martino RMC; Gentilomi GA; Varani S; Belluti F
Eur J Med Chem; 2018 May; 152():527-541. PubMed ID: 29758517
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, structure-activity relationships, and biological studies of chromenochalcones as potential antileishmanial agents.
Shivahare R; Korthikunta V; Chandasana H; Suthar MK; Agnihotri P; Vishwakarma P; Chaitanya TK; Kancharla P; Khaliq T; Gupta S; Bhatta RS; Pratap JV; Saxena JK; Gupta S; Tadigoppula N
J Med Chem; 2014 Apr; 57(8):3342-57. PubMed ID: 24635539
[TBL] [Abstract][Full Text] [Related]
16. β-Amino acid derivatives as mitochondrial complex III inhibitors of L. donovani: A promising chemotype targeting visceral leishmaniasis.
Chandrakar P; Gunaganti N; Parmar N; Kumar A; Singh SK; Rashid M; Wahajuddin M; Mitra K; Narender T; Kar S
Eur J Med Chem; 2019 Nov; 182():111632. PubMed ID: 31499363
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines.
Sunduru N; Nishi ; Palne S; Chauhan PM; Gupta S
Eur J Med Chem; 2009 Jun; 44(6):2473-81. PubMed ID: 19217698
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of in vitro antileishmanial efficacy of cyclosporin A and its non-immunosuppressive derivative, dihydrocyclosporin A.
Zheng ZW; Li J; Chen H; He JL; Chen QW; Zhang JH; Zhou Q; Chen DL; Chen JP
Parasit Vectors; 2020 Feb; 13(1):94. PubMed ID: 32085719
[TBL] [Abstract][Full Text] [Related]
19. Novel arylimidamides for treatment of visceral leishmaniasis.
Wang MZ; Zhu X; Srivastava A; Liu Q; Sweat JM; Pandharkar T; Stephens CE; Riccio E; Parman T; Munde M; Mandal S; Madhubala R; Tidwell RR; Wilson WD; Boykin DW; Hall JE; Kyle DE; Werbovetz KA
Antimicrob Agents Chemother; 2010 Jun; 54(6):2507-16. PubMed ID: 20368397
[TBL] [Abstract][Full Text] [Related]
20. In vivo antileishmanial action of Ir-(COD)-pentamidine tetraphenylborate on Leishmania donovani and Leishmania major mouse models.
Loiseau PM; Mbongo N; Bories C; Boulard Y; Craciunescu DG
Parasite; 2000 Jun; 7(2):103-8. PubMed ID: 10887656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
